Maffini F, Lepanto D, Chu F, Tagliabue M, Vacirca D, De Berardinis R
Int J Mol Sci. 2024; 25(17).
PMID: 39273632
PMC: 11395940.
DOI: 10.3390/ijms25179685.
Pfeuffer L, Siegert V, Frede J, Rieger L, Trozzo R, de Andrade Kratzig N
Blood Cancer J. 2024; 14(1):151.
PMID: 39198400
PMC: 11358282.
DOI: 10.1038/s41408-024-01123-6.
Soni D, Anjum Z, Raza K, Verma S
Cell Biochem Biophys. 2024; 82(2):575-591.
PMID: 38724755
DOI: 10.1007/s12013-024-01281-1.
Lampson B, Ramirez A, Baro M, He L, Hegde M, Koduri V
Cell. 2024; 187(9):2209-2223.e16.
PMID: 38670073
PMC: 11149550.
DOI: 10.1016/j.cell.2024.03.022.
Nayak L, Bettegowda C, Scherer F, Galldiks N, Ahluwalia M, Baraniskin A
Neuro Oncol. 2024; 26(6):993-1011.
PMID: 38598668
PMC: 11145457.
DOI: 10.1093/neuonc/noae032.
Research progress on the mechanism of common inflammatory pathways in the pathogenesis and development of lymphoma.
Shi A, Yun F, Shi L, Liu X, Jia Y
Ann Med. 2024; 56(1):2329130.
PMID: 38489405
PMC: 10946270.
DOI: 10.1080/07853890.2024.2329130.
Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis.
Wang Y, Xu Z, Wu K, Yu L, Wang C, Ding H
Proc Natl Acad Sci U S A. 2024; 121(5):e2312929121.
PMID: 38252825
PMC: 10835054.
DOI: 10.1073/pnas.2312929121.
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.
Karmali R, Galvez C, Hamadani M, Gordon L, Winter J, Ma S
Blood Adv. 2024; 8(7):1612-1620.
PMID: 38237077
PMC: 10987893.
DOI: 10.1182/bloodadvances.2023011369.
Analysis of genomic alterations in primary central nervous system lymphoma.
He X, Fan X, Shan Y, Ji X, Su L, Wang Y
Medicine (Baltimore). 2023; 102(35):e34931.
PMID: 37657032
PMC: 10476858.
DOI: 10.1097/MD.0000000000034931.
NF-κB subunits direct kinetically distinct transcriptional cascades in antigen receptor-activated B cells.
Zhao M, Chauhan P, Sherman C, Singh A, Kaileh M, Mazan-Mamczarz K
Nat Immunol. 2023; 24(9):1552-1564.
PMID: 37524800
PMC: 10457194.
DOI: 10.1038/s41590-023-01561-7.
Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Torka P, Thiruvengadam S, Chen L, Wang X, Chen C, Vuong D
Blood Cancer J. 2023; 13(1):9.
PMID: 36631449
PMC: 9834208.
DOI: 10.1038/s41408-022-00763-w.
Combining precision oncology and immunotherapy by targeting the MALT1 protease.
Mempel T, Krappmann D
J Immunother Cancer. 2022; 10(10).
PMID: 36270731
PMC: 9594517.
DOI: 10.1136/jitc-2022-005442.
B Lineage Cells in ANCA-Associated Vasculitis.
Merino-Vico A, van Hamburg J, Tas S
Int J Mol Sci. 2022; 23(1).
PMID: 35008813
PMC: 8745114.
DOI: 10.3390/ijms23010387.
Helicobacter pylori cagA status and gastric mucosa-associated lymphoid tissue lymphoma: a systematic review and meta-analysis.
Keikha M, Sahebkar A, Yamaoka Y, Karbalaei M
J Health Popul Nutr. 2022; 41(1):2.
PMID: 34980267
PMC: 8722127.
DOI: 10.1186/s41043-021-00280-9.
NF-κB signaling in inflammation and cancer.
Zhang T, Ma C, Zhang Z, Zhang H, Hu H
MedComm (2020). 2022; 2(4):618-653.
PMID: 34977871
PMC: 8706767.
DOI: 10.1002/mco2.104.
Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.
Lue J, OConnor O, Bertoni F
Ann Lymphoma. 2021; 4:7.
PMID: 34667996
PMC: 7611845.
DOI: 10.21037/aol-20-20.
NF-κB and Human Cancer: What Have We Learned over the Past 35 Years?.
Gilmore T
Biomedicines. 2021; 9(8).
PMID: 34440093
PMC: 8389606.
DOI: 10.3390/biomedicines9080889.
MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single-center experience.
Curran O, Poon M, Gilroy L, Torgersen A, Smith C, Al-Qsous W
Neurooncol Adv. 2021; 3(1):vdab090.
PMID: 34377990
PMC: 8349182.
DOI: 10.1093/noajnl/vdab090.
induces NF-κB signaling-driven peripheral T cell lymphoma.
Moon C, Reglero C, Cortes J, Quinn S, Alvarez S, Zhao J
Nat Cancer. 2021; 2(1):98-113.
PMID: 33928261
PMC: 8081346.
DOI: 10.1038/s43018-020-00161-w.
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Lee B, Lee H, Cho J, Yoon S, Kim S, Park W
Front Oncol. 2021; 11:628807.
PMID: 33777778
PMC: 7992425.
DOI: 10.3389/fonc.2021.628807.